Patient-oriented measures for phase 3 studies of tralokinumab for treatment of atopic dermatitis (ECZTRA 1, 2 and 3). Simpson EL, Wollenberg A, Soong W, Steffensen LA, et al. Ann Allergy Asthma Immunol 2022 Jul 14. pii: S1081-1206(22)00592.

Read + Share

Amedeo Smart

Independent Medical Education

Simpson EL, Wollenberg A, Soong W, Steffensen LA, et al. Patient-oriented measures for phase 3 studies of tralokinumab for treatment of atopic dermatitis (ECZTRA 1, 2 and 3). Ann Allergy Asthma Immunol 2022 Jul 14. pii: S1081-1206(22)00592.
PMID: 35843520